In this issue:
De-escalation of front-line Rd beneficial for elderly, intermediate-fit patients
Outcomes after delayed and second ASCT at relapse
MRD status is prognostic for outcome in transplant-eligible patients
MANHATTAN reports high MRD-negativity rates from upfront daratumumab-based quartet
Soluble BCMA levels predict progression to MM in MGUS and SMM
IKEMA: addition of Isatuximab to carfilzomib and dexamethasone extends PFS in RR
Adherence to oral antimyeloma therapy
OPTIMISMM: PFS benefit with addition of second-line pomalidomide in RR disease
APOLLO: daratumumab extends PFS when added to pomalidomide/dexamethasone in RRMM
Direct P70S6K1 inhibition can replace dexamethasone in synergistic combination with MCL-1 inhibition
Please login below to download this issue (PDF)